Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Sham-Injection Controlled, Double-Masked, Multicenter Trial of Ocriplasmin Intravitreal Injection for Treatment of Focal Vitreomacular Adhesion in Subjects With Exudative Age-Related Macular Degeneration (AMD)

NCT00913744 is registered in ClinicalTrials.gov with ThromboGenics as lead sponsor.

NCT NCT00913744
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00913744 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Sham-Injection Controlled, Double-Masked, Multicenter Trial of Ocriplasmin Intravitreal Injection for Treatment of Focal Vitreomacular Adhesion in Subjects With Exudative Age-Related Macular Degeneration (AMD)
Lead sponsor
ThromboGenics
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2010
Completion date
April 30, 2013
Enrollment
100 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

exudative age-related macular degeneration, focal vitreomacular adhesion